Changelog — 2026-02-11
2026-02-11
MDT
Medtronic plc
Status: RECRUITING → TERMINATED (PI left the institution. IRB study closure date of 11/12/202) — NA
NCT06775886
• Na • Status: Recruiting → Terminated • Why stopped: PI left the institution. IRB study closure date of 11/12/2025. IRB approved closeout on 2/6/2026.
🚩 MAJOR
2026-02-11
NVS
NOVARTIS AG
Enrollment 181→155 (-14%) — PHASE1
NCT07190300
• Phase 1 • Enrollment 181→155 (-14%)
MEDIUM
2026-02-11
MDT
Medtronic plc
Enrollment 40→60 (50%) — NA
NCT06703489
• Na • Enrollment 40→60 (+50%)
MEDIUM
2026-02-11
BSX
BOSTON SCIENTIFIC CORP
Enrollment 30→60 (100%) — NA
NCT06747013
• Na • Enrollment 30→60 (+100%)
MEDIUM
2026-02-11
PFE
PFIZER INC
Enrollment 32→5 (-84%) — PHASE2
NCT03913559
• Phase 2 • Enrollment 32→5 (-84%)
MEDIUM
2026-02-11
Z
ZNTL
Zentalis Pharmaceuticals, Inc.
Locations updated — PHASE2
NCT05128825
• Phase 2
MEDIUM
2026-02-11
R
RADX
Radiopharm Theranostics Ltd
Enrollment 35→30 (-14%) — EARLY_PHASE1
NCT06824155
• Early_Phase 1 • Enrollment 35→30 (-14%)
MEDIUM
2026-02-11
R
RADX
Radiopharm Theranostics Ltd
Locations updated — EARLY_PHASE1
NCT06824155
• Early_Phase 1
MEDIUM
2026-02-11
O
ONON
On Holding AG
Enrollment 55→70 (27%) — NA
NCT05810025
• Na • Enrollment 55→70 (+27%)
MEDIUM
2026-02-11
AZN
ASTRAZENECA PLC
Enrollment 10000→9000 (-10%)
NCT06521229
• Enrollment 10000→9000 (-10%)
MEDIUM
2026-02-11
G
GMAB
GENMAB A/S
Primary endpoint removed: Dose Escalation and Monotherapy Expansion Cohorts: Number of Participants With Shifts From Baseline in Safety Laboratory Parameters — PHASE1
NCT03917381
• Phase 1
MEDIUM
2026-02-11
D
DAN
DANA Inc
Enrollment 76→32 (-58%) — PHASE2
NCT06366347
• Phase 2 • Enrollment 76→32 (-58%)
MEDIUM
2026-02-11
R
RADX
Radiopharm Theranostics Ltd
Enrollment 23→30 (30%) — EARLY_PHASE1
NCT06305962
• Early_Phase 1 • Enrollment 23→30 (+30%)
MEDIUM
2026-02-11
R
RADX
Radiopharm Theranostics Ltd
Locations updated — EARLY_PHASE1
NCT06305962
• Early_Phase 1
MEDIUM
2026-02-11
NVS
NOVARTIS AG
Enrollment 36→24 (-33%) — PHASE1
NCT05944562
• Phase 1 • Enrollment 36→24 (-33%)
MEDIUM
2026-02-11
A
ACAD
ACADIA PHARMACEUTICALS INC
Locations updated — PHASE2
NCT07284667
• Phase 2
MEDIUM
2026-02-11
AMGN
AMGEN INC
Primary endpoint added: Percentage of Participants Who Had Thrombocytopenia-induced Dose Modification — PHASE3
NCT03362177
• Phase 3
MEDIUM
2026-02-11
NVO
NOVO NORDISK A S
Enrollment 3400→3439 (1%)
NCT04972721
• Enrollment 3400→3439 (+1%)
MEDIUM
2026-02-11
MDT
Medtronic plc
Enrollment 40→1 (-98%) — NA
NCT06775886
• Na • Enrollment 40→1 (-98%)
MEDIUM
2026-02-11
R
RVMD
Revolution Medicines, Inc.
Locations updated — PHASE3
NCT06881784
• Phase 3
MEDIUM